Vertex Pharmaceuticals received a boost with Canada's approval of ALYFTREK for cystic fibrosis. This approval boosts sentiment. The stock saw a 7% rise over the past month amid broader market optimism ...

Valued at a market cap of $117.7 billion, Vertex Pharmaceuticals Incorporated (VRTX) is a biotechnology company that ...

One of the brightest and most colorful stars in the sky and the most brilliant planet are on stage in the early morning dawn ...

BOSTON & OSAKA, Japan, June 23, 2025--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Ono Pharmaceutical Co., Ltd. (OTCMKTS: OPHLY) today announced an exclusive collaboration and license ...

PROVIDENCE — As Vertex Pharmaceuticals Inc. looks to consolidate its properties around Rhode Island, executives told state officials they plan to slash dozens of jobs and shutter two offices.

Defense in Karen Read trial proposes that Boston Police Officer John O'Keefe's death might be linked to a "jealousy"-fueled fight with ATF agent Brian Higgins.

Vertex had plans to hire 1,300 employees in Wilmington, but it never even got close.

Vertex's pipeline is poised to produce other big winners. I don't just think Vertex is a stock to buy on the dip -- I think it's a screaming buy.

Vertex Pharmaceuticals missed Wall Street estimates for quarterly results on Monday due to lower-than-expected sales of its cystic fibrosis (CF) drug Trikafta, sending shares down 2.5% after the bell.

Vertex Pharmaceuticals misses analyst estimates on the top and bottom lines in the first quarter. Vertex raises its full-year 2025 revenue guidance to a range of $11.85 billion to $12 billion ...

Investors eye Vertex’s Q1 for Alyftrek and Journavx momentum amid Trikafta’s international headwinds. Vertex stock shows a bullish technical bias despite recent pullback and mixed short-term ...

Vertex Pharmaceuticals is diversifying from its cystic fibrosis dominance into pain and other markets. Check out our recommendation for VRTX stock.